Disorders comorbid to attention deficit hyperactivity syndrome in children

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 107, Issue 7, 2007, Pages 30-35

  Zavadenko, N N ^a   Suvorinova, N Yu ^a  

^a NONE

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder (ADHD); Comorbid disorders

Indexed keywords

EID: 34548789540     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Russian source
2. Russian source
3. Russian source
4. Allen A., Kurlan R., Gilbert D. et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65: 1941-1949.
5. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000; 105: 1158-1170.
6. Angola A., Costello E., Erkanli A. Comorbidity. J Child Psychol Psychiat Allied Disciplines 1999; 40: 57-87.
7. Barkley R. Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiat Pract 2004; 10: 39-56.
8. Biederman J., Santangelo S., Faraone S. et al. Clinical correlates of enuresis in ADHD and non-ADHD children. J Child Psychol Psychiat 1995; 36: 865-877.
9. Biederman J., Faraone S., Milberger S. et al. Predictors and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Child Adolesc Psychiat 1996; 35: 343-351.
10. Biederman J., Spencer T., Newcorn J. et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology 2007; 190: 31-41.
11. Burns G., Walsh J. The influence of ADHD-hyperactivity/impulsivity symptoms on the development of oppositional defiant disorder symptoms in a 2-year longitudinal study. J Abnorm Child Psychol 2002; 30: 245-256.
12. Bymaster F., Katner J., Nelson D. et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 669-711.
13. Diagnostic and Statistical Manual of Mental Disorders (4th edition Revision) (DSM-IV-TR), by the American Psychiatric Association. Washington DC 2000.
14. Gresham F.M., MacMillan D.L., Bocian K.M. et al. Comorbidity of hyperactivity-impulsivity inattention and conduct problems: risk factors in social, affective, and academic domains. J Abnorm Child Psychol 1998; 26: 393-406.
15. Hazell Ph., Zhang S., Wolanczyk T. et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for ADHD. Eur Child Adol Psychiat 2006; 15: 105-110.
16. Hechtman L. Assessment and diagnosis of attention deficit/hyperactivity disorder. Child Adolesc Psychiat Clin N Am 2000; 9: 481-498.
17. Jensen P.S., Hinshaw S.P., Kraemer H.C. et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiat 2001; 40: 147-158.
18. Kadesjo B., Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiat Allied Disciplines 2001; 42: 487-492.
19. Kaplan S., Heiligenstein J., West S. et al. Efficacy and safety of atomoxetine in childhood attention deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004; 8: 45-52.
20. Kaufman J., Birmaher B., Brent D.A. et al. Diagnostic Interview Kiddie-Sads-Present and Lifetime Version (K-SADS-PL). University of Pittsburgh School of Medicine 1996.
21. Kratochvil C., Newcorn J., Arnold L. et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiat 2005; 44: 915-924.
22. Kuhne M., Schahar R., Tannock R. Impact of comorbid oppositional or conduct problems on attention deficit-hyperactivity disorder. J Am Child Adolesc Psychiat 1997; 36: 1715-1725.
23. Milberger S., Biederman J., Faraone S. V. et al. Attention deficit hyperactivity disorder and comorbid disorders: issues overlapping symptoms. Am J Psychiat 1995; 152: 1793-1799.
24. Newcorn J., Spencer T.J., Biederman J. et al. Atomoxetine treatment in children and adolescents with attentiondeficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiat 2005; 44: 240-248.
25. Ornitz E., Hanna G., De Traversay J. Prestimulation-induced startle modulation in ADHD and nocturnal enuresis. Psychophysiology 1992; 29: 437-451.
26. Robson W.L., Jackson H., Blackhurst D., Leung A.K. Enuresis in children with ADHD. South Med J 1997; 90: 503-505.
27. Spencer T., Heiligenstein J.H., Biederman J. et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention deficit hyperactivity disorder. J Clin Psychiat 2002; 63: 1140-1147.
28. Sumner C., Schuh K., Sutton V. et al. Placebo-Controlled Study of the Effects of Atomoxetine on Bladder Control in Children With Nocturnal Enuresis. J Child Adolesc Psychopharmacol 2006; 16: 699-711.
29. Sumner C., Sher L., Sutton V. et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. Neuropediatrics 2006; 37: 88.
30. Szatmari P., Offord D.R., Boyle M.H. Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder: findings from the Ontario Child Health Study. J Child Psychol Psychiat Allied Disciplines 1989; 30: 205-217.
31. Weiss M., Tannock R., Kratochvil Ch. et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adol Psychiat 2005; 44: 647-655.
32. Zametkin A.J., Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. New England J Med 1999; 340: 40-46.